These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

545 related articles for article (PubMed ID: 30907281)

  • 41. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
    Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
    IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The significance of PSA/IGF-1 ratio in differentiating benign prostate hyperplasia from prostate cancer.
    Koliakos G; Chatzivasiliou D; Dimopoulos T; Trachana V; Paschalidou K; Galiamoutsas V; Triantos A; Chitas G; Dimopoulos A; Vlatsas G
    Dis Markers; 2000; 16(3-4):143-6. PubMed ID: 11381196
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The quotient of prostate-specific antigen and prostate volume. Improved differentiation between benign prostatic hyperplasia and locally circumscribed prostate cancer].
    Semjonow A; Hamm M; Rathert P
    Urologe A; 1993 May; 32(3):250-3. PubMed ID: 7685557
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Significance and limitations of f/tPSA in differential diagnosis of prostate cancer with tPSA levels between 4 and 10 ng/ml].
    Chen ZD; Wei SM; Cai SL
    Zhonghua Wai Ke Za Zhi; 2004 May; 42(10):593-5. PubMed ID: 15265401
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
    Uno H; Koide T; Kuriyama M; Ban Y; Deguchi T; Kawada Y
    Hinyokika Kiyo; 1999 Jul; 45(7):457-61. PubMed ID: 10466060
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Minimum prostate-specific antigen (PSA) level diagnostic of prostate cancer.
    Yesner R; Kelly LJ; Chan YK
    Conn Med; 1996 Jul; 60(7):399-404. PubMed ID: 8758658
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Status of PSA determination for early detection of prostate carcinoma].
    Hammerer P; Huland H
    Versicherungsmedizin; 1995 Jun; 47(3):83-6. PubMed ID: 7541925
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.
    Oesterling JE; Jacobsen SJ; Chute CG; Guess HA; Girman CJ; Panser LA; Lieber MM
    JAMA; 1993 Aug; 270(7):860-4. PubMed ID: 7688054
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Optimum PSA reflex-range.
    Benecchi L
    Arch Ital Urol Androl; 2006 Jun; 78(2):44-8. PubMed ID: 16929601
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ratio of prostate specific antigen to the outer gland volume of prostrate as a predictor for prostate cancer.
    Zhang HM; Yan Y; Wang F; Gu WY; Hu GH; Zheng JH
    Int J Clin Exp Pathol; 2014; 7(9):6079-84. PubMed ID: 25337254
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
    Khan MA; Partin AW; Rittenhouse HG; Mikolajczyk SD; Sokoll LJ; Chan DW; Veltri RW
    J Urol; 2003 Sep; 170(3):723-6. PubMed ID: 12913682
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Usefulness and predictive value of PSA density, adjusted by transition zone volume, in men with PSA levels between 2 and 4 ng/ml].
    Janane A; Hajji F; Ismail T; Jawad C; Elondo JC; Dakka Y; Ghadouane M; Ameur A; Abbar M; Albouzidi A
    Actas Urol Esp; 2012 Feb; 36(2):93-8. PubMed ID: 22188752
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Histopathologic characterization of prostate diseases in Madinah, Saudi Arabia.
    Albasri A; El-Siddig A; Hussainy A; Mahrous M; Alhosaini AA; Alhujaily A
    Asian Pac J Cancer Prev; 2014; 15(10):4175-9. PubMed ID: 24935366
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Potential biomarkers for differentiation of benign prostatic hyperplasia and prostate cancer.
    El Melegy NT; Aboulella HA; Abul-Fadl AM; Mohamed NA
    Br J Biomed Sci; 2010; 67(3):109-12. PubMed ID: 20973404
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
    Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
    Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A panel of selected serum protein biomarkers for the detection of aggressive prostate cancer.
    Song J; Ma S; Sokoll LJ; Eguez RV; Höti N; Zhang H; Mohr P; Dua R; Patil D; May KD; Williams S; Arnold R; Sanda MG; Chan DW; Zhang Z
    Theranostics; 2021; 11(13):6214-6224. PubMed ID: 33995654
    [No Abstract]   [Full Text] [Related]  

  • 57. Serum prostate specific antigen levels in men with benign prostatic hyperplasia and cancer of prostate.
    Amayo A; Obara W
    East Afr Med J; 2004 Jan; 81(1):22-6. PubMed ID: 15080511
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of prostate-specific antigen density in benign prostatic hyperplasia and prostate carcinoma. Preliminary results.
    Akdaş A; Dillioğlugil O; Cevik I; Ilker Y
    Eur Urol; 1994; 25(4):299-303; discussion 304. PubMed ID: 7519992
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Determination of serum prostate-specific antigen-alpha1-antichymotrypsin complex for diagnosis of prostate cancer in Japanese cases.
    Kuriyama M; Abrahamsson PA; Imai K; Akimoto S; Deguchi N; Shichiri Y; Sugiyama Y; Niwa T; Inoue T
    Scand J Urol Nephrol; 2001 Feb; 35(1):5-10. PubMed ID: 11291689
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combination of Autoantibody Signature with PSA Level Enables a Highly Accurate Blood-Based Differentiation of Prostate Cancer Patients from Patients with Benign Prostatic Hyperplasia.
    Leidinger P; Keller A; Milchram L; Harz C; Hart M; Werth A; Lenhof HP; Weinhäusel A; Keck B; Wullich B; Ludwig N; Meese E
    PLoS One; 2015; 10(6):e0128235. PubMed ID: 26039628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.